Literature DB >> 659966

Human plasma prekallikrein (Fletcher factor) clotting activity and antigen in health and disease.

H Saito, M C Poon, W Vicic, G H Goldsmith, J E Menitove.   

Abstract

Human plasma prekallikrein (Fletcher factor) clotting activity and antigen levels have been examined in various clinical conditions. Prekallikrein antigen was measured by a newly developed, specific, and sensitive radioimmunoassay. The assay had no demonstrable cross-reactivity with human urinary kallikrein nor, in the species tested, animal plasma prekallikrein. This assay was able to measure plasma kallikrein after its biological functions had been inactivated by plasma inhibitors. Normal human pooled plasma contained approximately 50 microgram/ml prekallikrein. Quantitative measurement of plasma prekallikrein was possible for concentrations as low as 0.3% of that of normal pooled plasma. A good correlation (correlation coefficient = 0.71) existed between titers of plasma prekallikrein measured by Fletcher factor clotting assays and radioimmunoassays among 40 normal subjects. Both prekallikrein clotting activity and antigen were significantly reduced in plasmas of patients with advanced hepatic cirrhosis or DIC. Prekallikrein activity and antigen were mildly decreased in plasmas or serums of patients with chronic renal failure and nephrotic syndrome but were normal in those of patients under treatment with warfarin or suffering from SLE, rheumatoid arthritis, sarcoidosis, or HANE. Human cord serum contained a lower titer of prekallikrein antigen than adult serum. Strenuous physical exercise did not significantly change plasma prekallikrein levels.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 659966

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  5 in total

1.  Inhibition of prekallikrein activation in human plasma by components of bovine plasma.

Authors:  K M Weerasinghe; E P Kirby
Journal:  Inflammation       Date:  1992-10       Impact factor: 4.092

2.  Studies of the kallikrein-kinin system in patients with sickle cell anemia.

Authors:  R L Miller; P S Verma; R G Adams
Journal:  J Natl Med Assoc       Date:  1983-06       Impact factor: 1.798

3.  Inhibitory spectrum of alpha 2-plasmin inhibitor.

Authors:  H Saito; G H Goldsmith; M Moroi; N Aoki
Journal:  Proc Natl Acad Sci U S A       Date:  1979-04       Impact factor: 11.205

4.  Prekallikrein activation in human, bovine, and rabbit plasmas: presence of an inhibitor in bovine plasma.

Authors:  K M Weerasinghe
Journal:  Inflammation       Date:  1992-06       Impact factor: 4.092

5.  Kallikrein-kinin system in chronic subdural haematomas: its roles in vascular permeability and regulation of fibrinolysis and coagulation.

Authors:  H Fujisawa; H Ito; S Kashiwagi; S Nomura; M Toyosawa
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-10       Impact factor: 10.154

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.